Loading
A phase 1/2 trial of Giredestrant, Abemaciclib, Ipatasertib, Inavolisib, Ribociclib and Everolimus in HR-positive / HER2-negative breast cancer, run by Hoffmann-La Roche, now recruiting.
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer is a phase 1/2 interventional study registered as NCT04802759 by Hoffmann-La Roche, with 316 participants planned, started 2021-06-22 and due to reach its primary completion in 2029-05-30. Interventions recorded: Giredestrant, Abemaciclib, Ipatasertib, Inavolisib, Ribociclib and Everolimus.
Shares Giredestrant, Flatiron Health (Roche), Ribociclib, Abemaciclib and the tag pipeline.
Shares Giredestrant, Inavolisib, Flatiron Health (Roche), Ribociclib and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Abemaciclib, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Inavolisib, Flatiron Health (Roche), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Inavolisib, Flatiron Health (Roche), Ribociclib and the tag pipeline.
Shares Ribociclib, Abemaciclib, Everolimus and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche) and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), HR-positive / HER2-negative breast cancer and the tag pipeline.